FY26 annual report flags funding strain and six subsidiary approvals
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's 34th annual general meeting is set for 30 November 2026 at 3:00 p.m. IST via video conference. Two years of funding constraints hindered expansion, and an October 2026 rights issue aims to strengthen capital and cash flow. Shareholders will approve FY26 audited accounts, reappoint G. Swaminathan, appoint a secretarial auditor for five years, and approve transactions with six subsidiaries, each capped at Rs 25 crore for FY27.
Funding needs and possible dilution from the rights issue are concerns. The Rs 150 crore subsidiary transaction ceiling needs careful review.